bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: M A M F J
2018: D N O S A J J M

 
  Other news for:
Breast Neoplasms
 Resources from HONselect
Ibrance Approval Expanded to Include Men With Breast Cancer

By Scott Roberts

THURSDAY, April 4, 2019 (HealthDay News) -- U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or spreading (metastatic) breast cancer, the agency said Thursday in a news release.

"Today we are expanding the indication for Ibrance to include male patients based upon data from postmarketing reports and electronic health records showing that the safety profile for men treated with Ibrance is consistent with the safety profile in women treated with Ibrance," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence.

Breast cancer among men is rare -- just 2,670 cases are estimated for all of 2019, which represents fewer than 1 percent of all predicted cases of the disease. Men are more likely to be diagnosed at an older age with a more advanced stage of the disease, the FDA said.

Ibrance was first approved in 2015. It is a kinase inhibitor, approved in combination with an aromatase inhibitor as the first hormonal-based therapy in women who have gone through menopause.

Ibrance's most common side effects are infections, low levels of white blood cells, fatigue, nausea, inflammation of the mouth and lips, anemia, hair loss and diarrhea.

Doctors should tell male patients with female partners of child-bearing age to use contraception during treatment with Ibrance and for three months after the last dose, the agency advised.

Ibrance is produced by Pfizer, based in New York City.

More information

Learn more about this approval.

Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=744719

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Men
Breast
Breast Neoplasms
Neoplasms
Women
Infection
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact